NCT07886320 Adapalene Gel for Acute Radiation-Induced Skin Injury
| NCT ID | NCT07886320 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Yunnan Cancer Hospital |
| Condition | Radiation Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 50 participants in total. It began in 2026-03-01 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
his study aims to evaluate whether adapalene gel is effective and safe for treating acute radiation-induced skin injury in adults receiving radiotherapy. Researchers will compare adapalene gel with Biafine to determine whether adapalene gel reduces radiation-induced skin injury and improves symptoms. The main questions are: Does adapalene gel reduce the severity of acute radiation-induced skin injury compared with Biafine, and what medical problems or adverse events occur in participants using adapalene gel? Participants will apply adapalene gel or Biafine topically every day throughout the course of radiotherapy, visit the clinic every 5 days for examinations and tests, and record their symptoms and any adverse reactions during use.
Eligibility Criteria
Inclusion Criteria: * Informed consent: All subjects must voluntarily participate in the study and sign a written informed consent form that meets the requirements of the ethics committee. * Male or female, aged between 18 and 75 years. * Histologically or cytologically confirmed breast cancer or squamous cell carcinoma of the head and neck. * Planned to receive involved-field radiotherapy (post-breast cancer surgery whole breast/chest wall ± regional lymph node irradiation). Exclusion Criteria: * Patients unable to cooperate with the study: cognitive impairment, severe mental illness, communication disorders, or other reasons (such as extreme anxiety, uncontrollable pain) that prevent understanding and active cooperation with the research process and postoperative care. * Any previous or current illnesses, treatments, or laboratory abnormalities that may confound the study results, affect the subjects' full participation in the study, or involve participation that may not be in the subjects' best interests.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07886320 clinical trial?
This trial is open to female participants only, studying Radiation Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07886320 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07886320 currently recruiting?
Yes, NCT07886320 is actively recruiting participants. Contact the research team at 2489181721@qq.com for enrollment information.
Where is the NCT07886320 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT07886320 clinical trial?
NCT07886320 is sponsored by Yunnan Cancer Hospital. The trial plans to enroll 50 participants.